VBI Vaccines (NASDAQ:VBIV) insider Francisco Diaz-Mitoma bought 10,000 shares of the stock in a transaction that occurred on Friday, May 11th. The shares were purchased at an average price of $3.05 per share, for a total transaction of $30,500.00. Following the purchase, the insider now owns 268,839 shares in the company, valued at approximately $819,958.95. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
VBIV stock remained flat at $$3.44 during mid-day trading on Thursday. 3,110 shares of the company’s stock traded hands, compared to its average volume of 143,124. VBI Vaccines has a 1-year low of $3.20 and a 1-year high of $3.33. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.72 and a current ratio of 3.77.
VBI Vaccines (NASDAQ:VBIV) last announced its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.03). The company had revenue of $0.18 million during the quarter, compared to analysts’ expectations of $0.21 million. VBI Vaccines had a negative return on equity of 47.54% and a negative net margin of 4,607.13%. equities analysts expect that VBI Vaccines will post -0.7 earnings per share for the current fiscal year.
A number of hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. lifted its stake in VBI Vaccines by 7.3% in the 1st quarter. Russell Investments Group Ltd. now owns 491,449 shares of the biopharmaceutical company’s stock worth $1,720,000 after purchasing an additional 33,588 shares in the last quarter. Meitav Dash Investments Ltd. purchased a new stake in VBI Vaccines in the 4th quarter worth $4,664,000. Millennium Management LLC lifted its stake in VBI Vaccines by 92.8% in the 4th quarter. Millennium Management LLC now owns 245,603 shares of the biopharmaceutical company’s stock worth $1,049,000 after purchasing an additional 118,208 shares in the last quarter. TIAA CREF Investment Management LLC lifted its stake in VBI Vaccines by 24.8% in the 4th quarter. TIAA CREF Investment Management LLC now owns 78,369 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 15,557 shares in the last quarter. Finally, California State Teachers Retirement System lifted its stake in VBI Vaccines by 52.5% in the 4th quarter. California State Teachers Retirement System now owns 54,460 shares of the biopharmaceutical company’s stock worth $233,000 after purchasing an additional 18,760 shares in the last quarter. Institutional investors and hedge funds own 48.51% of the company’s stock.
About VBI Vaccines
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.